|
Wednesday, November 14, 2007
Abraxis BioScience Spins off From APP Pharmaceuticals
Los Angeles-based Abraxis BioScience said this morning that it has spun-off from APP Pharmaceuticals, the firm said today. The firm will focus on drug development. The firm's major product, ABRAXANE, is used for treating cancer and other illnesses. According to Abraxis, it has been capitalized with $700M in cash and it will trade on the Nasdaq Global Market as ABII.
posted on Wednesday, November 14, 2007
|
 RSS
 Email
Twitter
Previous news:
Wednesday, July 8, 2009
Monday, July 6, 2009
Thursday, July 2, 2009
Wednesday, July 1, 2009
Tuesday, June 30, 2009
|
